We focus on
Tricuspid Valve Regurgitation
Clinical Problem and Unmet Need
The tricuspid valve allows the blood from the right atrium to move to the right ventricle without obstruction or regurgitation. When the tricuspid valve 'regurgitates', blood moves back into the atrium from the ventricle. Left untreated, tricuspid regurgitation (TR) leads to serious clinical complications and premature mortality.
Significant TR affects an approximate 1.6 million people in the U.S., where 200,000 new cases emerge every year. Patients with significant TR are often hospitalized, suffer from a poor quality of life and experience a large risk of death, which parallels the degree of valve leakage. These patients are mostly elderly and less than 5% of them are treated with open heart surgery, which carries a significant risk. For most patients, medications to temporarily relieve the consequences of TR are the only option, which fails to address the root cause of the problem.
Thus, the need for new options to treat TR is both undisputed and urgent. Novel solutions must be safely applicable to the large number of patients affected by TR and require minimally invasive approaches that take into account the characteristic specifics to the tricuspid valve including the anatomy of the valve and adjacent structures and the fragility of the tissues on the right side of the heart.
Tricuspid regurgitation results in...
Undertreatment
.png&w=384&q=75)
Less than 5% of patients are operated after their diagnosis
Poor Quality of Life
Patients with TR frequently suffer from heart and renal failure, resulting in repeated hospitalization
Poor Survival
Less than 50% survive more than 5 years after diagnosis
We need better treatment
Our Technology
Our tricuspid regurgitation treatment system is a novel approach designed for percutaneous implantation. Our system integrates components developed through a multidisciplinary collaboration that brings together clinical and cardiac imaging expertise, with advanced cardiac device engineering.
Our approach is distinctly characterized by:
- A proprietary anchoring system allowing robust and precise positioning and steering of the prosthetic valve in the optimal position in the tricuspid regurgitant orifice
- A novel prosthetic design allowing optimal interaction with the native tissue and annulus to avoid tissue and conduction system disruption and optimally preventing residual regurgitation and thrombus formation
Interested in learning more?
Dr. Sarano's lectures provide insight into the years of research that have formed the basis of this invention.
There's plenty to learn in this publication